J
Joel M. Reid
Researcher at Mayo Clinic
Publications - 274
Citations - 11448
Joel M. Reid is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pharmacokinetics & Medicine. The author has an hindex of 50, co-authored 248 publications receiving 10094 citations. Previous affiliations of Joel M. Reid include Oregon Health & Science University & Upjohn.
Papers
More filters
Journal ArticleDOI
A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.
Wen Son Hsieh,Eng Huat Tan,Wan-Teck Lim,Ross A. Soo,Anthony T.C. Chan,Edwin P. Hui,Soo-Chin Lee,John Soon Wah Low,Pei Li Lim,Thomas Kwok Seng Loh,Matthew M. Ames,Joel M. Reid,Paul Murray,Qian Tao,Boon Cher Goh,Richard F. Ambinder +15 more
TL;DR: Patients with relapsed or refractory NPC and NK-T cell lymphomas were enrolled to determine safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity using a dose escalation design.
Journal ArticleDOI
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
Sarah Leary,Julie R. Park,Joel M. Reid,Andrew T. Ralya,Sylvain Baruchel,Bing Wu,Ashish M. Ingle,Charlotte H. Ahern,Brenda J. Weigel,Susan M. Blaney +9 more
TL;DR: Tbananib is a first-in-class peptibody (peptide-Fc fusion protein) that selectively inhibits Angiopoietin 1 and AngiopOietin 2 to inhibit interaction with the Tie2 receptor tyros...
Journal ArticleDOI
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
Kristina A. Cole,Heba Ijaz,Lea F. Surrey,Mariarita Santi,Xiaowei Liu,Charles G. Minard,John M. Maris,Stephan D. Voss,Joel M. Reid,E. Fox,Brenda J. Weigel +10 more
TL;DR: In this paper , the authors reported the pediatric solid tumor phase 2 results of the ADVL1312 trial combining irinotecan and adavosertib (AZD1775).
Proceedings ArticleDOI
Abstract 2283: Endoxifen exhibits potentin vitroandin vivoantitumor activity in ER+/HER2+ breast cancer and tamoxifen refractory tumors
Kathryn E. Reinicke,Xiaonan Hou,Matthew P. Goetz,Vera J. Suman,Mary J. Kuffel,Paul Haluska,Joel M. Reid,Matthew M. Ames +7 more
TL;DR: Endoxifen, unlike Tam, potently inhibits growth in both ER+ and ER+/HER2+ breast cancer cell lines at concentrations observed in human CYP2D6 intermediate and extensive metabolizers (>40 nM).
Proceedings ArticleDOI
Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors
Emily J. Koubek,Brian A. Costello,Jun Yin,Renee M. McGovern,Sarah A. Buhrow,Renee A. Schoon,Carrie Strand,Yixing Jiang,Mitesh J. Borad,Naoko Takebe,Scott H. Kaufmann,Alex A. Adjei,Joel M. Reid +12 more
TL;DR: No correlation was found between navitoclax exposure and apoptosis as indicated by cytokeratin-18 cleavage and the pharmacokinetics and pharmacodynamics of both agents in combination were found.